Coronavirus disease CIVID-19 - unused therapy opportunities

A.A. Gromov ^1,2, M.V. Kruchinina ¹, A.V. Rabko ^1,2

¹ Research Institute of Therapy and Preventive Medicine - a branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk

² LLC Center for the prevention of thrombosis, Novosibirsk

High mortality and the enormous socio-economic consequences of the COVID-19 virus epidemic require the immediate development of effective treatment methods. The main complication of coronovirus infection, leading to the development of a fatal outcome, is pneumonia, respiratory and multiple organ failure, which develop in some patients with COVID-19 infection.

An analysis of the clinical, laboratory and pathoanatomical picture of the SARS-CoV-2 virus lesion according to the literature suggests that there are disturbances in the microcirculation and oxygen transportation, erythrocyte hemolysis, intraalveolar fibrinogenesis and microthrombogenesis in the pathogenesis of patients, which fits into the picture of chronic hemolytic microtrombovascular syndrome of second and second intravascular coagulation (chronic DIC).

The prevention of these processes, preventive and early therapy, the combined use of anticoagulants, antiplatelet agents of the erythrocyte series, membrane-stabilizing drugs and, possibly, mild thrombolytic drugs for outpatient use, according to the authors, can prevent the development of life-threatening complications and reduce mortality of patients COVID-19.

Early prophylactic therapy with anticoagulants, antiplatelet agents and membrane-stabilizing drugs, an early treatment regimen for pneumonia with outpatient thrombolytic drugs and anticoagulants are proposed. To prevent hemorrhagic complications, two schemes for identifying risk groups for hemorrhagic complications and the use of thrombolytic therapy in these patients in lower doses have been proposed.

Keywords: SARS-CoV-2, COVID-19, microthrombosis, microcirculatory disorders, anticoagulant therapy, antiplatelet agents, red blood cells

For citation: Gromov A.A., Kruchinina M.V., Rabko A.V. COVID-19: therapy possibilities in reserve. RMJ. 2020;9:2–6.